Promising drug cocktail aims to stop smoldering myeloma before it starts

This study tests whether a combination of three drugs (daratumumab, carfilzomib, and dexamethasone, known as DKd) can prevent or delay the development of full-blown multiple myeloma in people with high-risk smoldering multiple myeloma. Fourteen adults with this condition will receive the drugs in cycles over about a year, followed by daratumumab alone. The goal is to see if this treatment can achieve a deep remission and stop the disease from progressing.